Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
) k9 y) Y' C3 V3 \NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
' I& d$ f, c/ d y+ Author Affiliations( f$ Z, o2 t/ N( x2 \
" M4 y0 J( g6 s7 ^$ t
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan ; T& F8 f3 f, F w
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan ' e% J! D8 L7 b2 _0 x# G. `6 J
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
8 f$ X% w$ p* C( ]1 V: x- t W) \4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
+ H% O" z* X& U, f5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
' o( Z g4 H" x' N1 u) H6 G6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan / C6 F+ \; [9 o4 W
7Kinki University School of Medicine, Osaka 589-8511, Japan 8 |- \+ S Q9 [, W- ~. _
8Izumi Municipal Hospital, Osaka 594-0071, Japan 0 @) E4 |7 v6 |; ~8 \
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan - X( n' c# C+ x' ~
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
; @3 w. P$ K5 c" QAbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. / x, G3 [) ?2 ` J i% Y
3 r' r2 W& N3 I5 F) i* A8 Z
|